Literature DB >> 9404965

Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases.

M R Lucey1, K A Brown, G T Everson, J J Fung, R Gish, E B Keeffe, N M Kneteman, J R Lake, P Martin, S V McDiarmid, J Rakela, M L Shiffman, S K So, R H Wiesner.   

Abstract

This report summarizes a recent meeting cosponsored by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases to formulate minimal criteria by which patients with severe liver disease will be placed on the waiting list for liver transplantation. The participants agreed that only patients in immediate need of liver transplantation should be placed on the waiting list. Patients should not be placed in anticipation of some future need for such therapy. It was agreed that minimal criteria could assist but not replace the clinical judgment of the transplant professionals at individual centers. The criteria will be summarized below for adult patients with acute or chronic liver disease. The most important non-disease-specific criterion for placement on the transplant waiting list was an estimated 90% chance of surviving 1 year. This translated into a Child-Pugh score of > or = 7 for patients with cirrhosis which places the patient in Child-Pugh class B or C. Cirrhotic patients who have experienced gastrointestinal bleeding caused by portal hypertension or a single episode of spontaneous bacterial peritonitis would meet the minimal criteria irrespective of their Child-Pugh score. There were disease-specific criteria also. These include a sole minimal criterion for patients with fulminant hepatic failure regardless of etiology of the onset of stage 2 hepatic encephalopathy. A requirement for 6 months abstinence from alcohol before placement on the transplant waiting list was considered appropriate for most patients with alcoholic liver disease. Exceptional cases could get access to the waiting list through a regional review process. Chronic cholestatic diseases present difficulties because of a different natural history than that of chronic hepatocellular diseases. The use of specific risk scores for primary biliary cirrhosis and primary sclerosing cholangitis will likely replace Childs-Pugh classification as the scoring systems become refined. Minimal criteria for any patient with a primary hepatocellular cancer would admit any patient with a tumor confined to the liver irrespective of size or number of tumors, after careful investigation had failed to show spread to lymph nodes, the portal vein, or distant organs. Unusual or rare indications for liver transplantation, including Budd-Chiari syndrome, Wilson's disease, and other hereditary disorders, were also discussed. Finally, it was agreed that there should be no absolute contraindications to placement of patients on the liver transplant waiting list. These criteria should be open to regular review to accommodate advances in the field.

Entities:  

Mesh:

Year:  1997        PMID: 9404965     DOI: 10.1002/lt.500030613

Source DB:  PubMed          Journal:  Liver Transpl Surg        ISSN: 1074-3022


  55 in total

1.  Studies on avian erythrocyte metabolism--I. Procedure for separation and quantitation of the major phosphorylated metabolic intermediates by anion exchange chromatography.

Authors:  R E Isaacks; D R Harkness; G A Froeman; S A Sussman
Journal:  Comp Biochem Physiol A Comp Physiol       Date:  1976-01

2.  Little response of cerebral metastasis from hepatocellular carcinoma to any treatments.

Authors:  Jung Ho Han; Dong Gyu Kim; Jung Cheol Park; Hyun-Tai Chung; Sun Ha Paek; Young Seob Chung
Journal:  J Korean Neurosurg Soc       Date:  2010-05-31

3.  Liver transplantation in acute alcoholic hepatitis: Current status and future development.

Authors:  Ashwani K Singal; Andrea Duchini
Journal:  World J Hepatol       Date:  2011-08-27

4.  Endoscopic treatment of biliary tract disease prior to orthotopic liver transplantation.

Authors:  Roshan Shrestha; David M S Grunkemeier
Journal:  Curr Treat Options Gastroenterol       Date:  2006-04

5.  Ethnic disparities in liver transplantation.

Authors:  Nyingi Kemmer
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-05

6.  Diagnosis and management of fulminant Wilson's disease: a single center's experience.

Authors:  Yi Tian; Guo-Zhong Gong; Xu Yang; Feng Peng
Journal:  World J Pediatr       Date:  2015-06-04       Impact factor: 2.764

Review 7.  It Is Not All About Pretransplant Factors: Posttransplant Complications Alter the Risk of Alcohol Relapse.

Authors:  Toshihiro Kitajima; Shunji Nagai; Dilip Moonka; Antu Segal; Marwan S Abouljoud
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-06-30

8.  Early liver transplant for severe alcoholic hepatitis: establishing a new frontier by ignoring the rule?

Authors:  Julie Zhu; Trana Hussaini; Eric M Yoshida
Journal:  Ann Transl Med       Date:  2018-10

9.  Total pancreatectomy and islet autotransplantation in chronic pancreatitis: recommendations from PancreasFest.

Authors:  Melena D Bellin; Martin L Freeman; Andres Gelrud; Adam Slivka; Alfred Clavel; Abhinav Humar; Sarah J Schwarzenberg; Mark E Lowe; Michael R Rickels; David C Whitcomb; Jeffrey B Matthews; Stephen Amann; Dana K Andersen; Michelle A Anderson; John Baillie; Geoffrey Block; Randall Brand; Suresh Chari; Marie Cook; Gregory A Cote; Ty Dunn; Luca Frulloni; Julia B Greer; Michael A Hollingsworth; Kyung Mo Kim; Alexander Larson; Markus M Lerch; Tom Lin; Thiruvengadam Muniraj; R Paul Robertson; Seth Sclair; Shalinender Singh; Rachelle Stopczynski; Frederico G S Toledo; Charles Melbern Wilcox; John Windsor; Dhiraj Yadav
Journal:  Pancreatology       Date:  2013-11-13       Impact factor: 3.996

Review 10.  [Psychiatric assessment of alcoholic patients on a waiting list for liver transplantation: which prognostic criteria are empirically proven?].

Authors:  M Soyka; F Stickel
Journal:  Nervenarzt       Date:  2013-09       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.